Insider buying
~$2.3K11K sh @ $0.21
Traded Sep 16 · filed 1 day later
The CEO of Aim Immunotech paid $2.3K out of pocket for Aim Immunotech shares. Shares held went up 12% with this purchase.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Sep 17, 2026 · Filed Sep 18, 2026
The CEO of Aim Immunotech paid $5K out of pocket for Aim Immunotech shares. Shares held went up 23% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$4,992
Shares × reported transaction price
<$25K
+23.3%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 0 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 3 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the CEO's reported total pay for fiscal 2025 ($640K)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-09-30. The proxy names Thomas K. Equels as CEO for that year. A size comparison, not a judgement
38 days after results of Aug 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $0.2173 on Sep 17, 2026, within 3% of its 52-week low, after a 23% drop over the previous 30 trading days
52-week range $0.212 (Sep 16, 2026) to $2.88 (Sep 25, 2025), 0% of the way up, from 251 adjusted closes. 30 trading days earlier: $0.2836 on Aug 5, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −12.0% | −1.0% | −11.0% |
| 30 days | −18.9% | −0.1% | −18.8% |
Past results only. Not a forecast.
Insider buying
Traded Sep 16 · filed 1 day later
The CEO of Aim Immunotech paid $2.3K out of pocket for Aim Immunotech shares. Shares held went up 12% with this purchase.
Insider buying
Traded Sep 15 · filed 1 day later
The CEO of Aim Immunotech paid $4.9K out of pocket for Aim Immunotech shares. Shares held went up 32% with this purchase.
Insider buying
First insider buy since Jun 2025Traded Sep 14 · filed 1 day later
The CEO of Aim Immunotech paid $1.3K out of pocket for Aim Immunotech shares. Shares held went up 9% with this purchase.
Thomas K Equels, CEO & President's past purchases, 90 days after disclosure: 5 buys, median −40.0 pts vs S&P 500, beat it 0 of 5 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.